CD95 ligand: Lethal weapon against malignant glioma?

Brain Pathology

Volumn 8, Issue 2, 1998, Pages 285-293

  Weller, Michael ^a   Kleihues, Paul ^b   Dichgans, Johannes ^a   Ohgaki, Hiroko ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; GLIOBLASTOMA; HUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE;

EID: 0031923778     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1998.tb00154.x     Document Type: Review

References (67)

1. Alderson LM, Castleberg RL, Harsh GR, Louis DN, Henson JW (1995) Human gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001
2. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PI, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762
3. Cheng AHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966-1968
4. Ellison DW, Steart PV, Gatter KC, Weller RO (1995) Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 21: 352-361
5. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50
6. Färkkila M, Jääskeläinen J, Kallio M, Blomstedt G, Raininko R, Virkkunen P, Paetau A, Sarelin H. Mäntyla M (1994) Randomised, controlled trial of intratumoral recombinant γ-Interferon treatment in newly diagnosed glioblastoma. Br J Cancer 70:138-141
7. Friesen C, Herr l, Krammer PH, Debatin KM (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med 2: 574-577
8. Fujisawa K, Asahara H, Okamoto K. Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T, Nishioka T (1996) Therapeutic effect of the anti-fas antibody on arthritis in HTLV-I tax transgenic mice. J Clin Invest 98: 271-278
9. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H (1997) Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors. Brain Pathol 7: 863-869
10. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366
11. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, Lach B, Chatten J, Reed JC (1997) Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 150: 805-814
12. Krishna M, Smith TW, Recht LD (1995) Expression of bcl2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J Neurosurg 83: 1017-1022
13. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter M (1997) FLICE is activated by association with the CD95 death-inducing signalling complex. EMBO J16: 2794-2804
14. Midis GP, Shen Y, Owen-Schaub L (1996) Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56: 3870-3874
15. Mizuno M, Yoshida J (1996) Tumor necrosis factor-α gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells. Jpn J Cancer Res 87: 543-547
16. Müller M, Strand S, Hug H, Heinemann EM, Walczak H. Hofmann WJ, Stremmel W, Krammer PH, Galle PR (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99: 403-413
17. Nagata S, Golstein P (1995) The Fas death factor. Science 267: 1449-1456
18. Nakasu S, Nakasu Y, Nioka H, Nakajima M, Handa J (1994) Bcl-2 protein expression in tumors of the central nervous system. Acta Neuropathol 88: 520-526
19. Newcomb EW, Bhaila SK, Parrish CL, Hayes RL, Cohen H, Miller DC (1997) Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol 94: 369-375
20. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA(1997) Human lung carcinomas express Fas ligand. Cancer Res 57: 1007- 1012
21. O'Conneil J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184- 1075-1082
22. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A. Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809
23. Ohta S, Mizuno M, Takaoka T, Yoshida J (1997) Augmentation of anti-Fas antibody-mediated apoptosis on human glioma cells by liposomes associated with the antibody. J Neuro-Oncol 35: 7-11
24. Owen-Schaub LB, Zhang W, Cusack JC. Angelo LS, Santee SM. Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-40
25. Pan G, Ni J, Wei YF, Yu GL, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
26. Peter ME, Chinnayan A, Hellbardt S. Kischkel F, Krammer PH, Dixit VM (1996) The CD95 (APO-1/Fas) associating signalling molecules. Cell Death Differ 2: 161-170
27. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A (1995) Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25: 2253-2258
28. Richardson BC, Lalwani ND, Johnson KJ, Marks RM (1994) Fas ligation triggers apoptosis in macrophages but not endotheiial cells. Eur J Immunol 24: 2640-2645
29. Rieger L, Weller M, Bornemann A, Schabet M, Dichgans J, Meyermann R (1998) BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci in press
30. Roth W, Fontana A, Trepel M, Dichgans J, Reed JC, Weller M (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 5563
31. Roth W, Wagenknecht B, Grimmel C, Dichgans J, Weller M (1998) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. Br J Cancer 77: 404-411
32. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G (1997) Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99: 1173-1178
33. Safayhi H, Mack T, Sabieraj J, Ammon HPT (1992) Boswellic acids: Novel, specific nonredox inhibitors of 5lipoxygenase. J Pharmacol Exp Ther261:1143-1146
34. Sakahira H, Enari M, Nagata S (1998) Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 391: 96-99
35. Schulz JB, Weller M, Klockgether T (1996) A sequential requirement for new mRNA and protein synthesis, ICElike protease activity, and free radicals in potassium deprivation-induced apoptosis of cerebellar granule cells. J Neurosci 16: 4696-4706
36. Schulz JB, Bremen D, Reed JC, Lommatzsch J, Takayama S, Wüllner U, Löschmann PA, Klockgether T, Weller M (1997) Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species. J Neurochem 69: 2075-2086
37. Seino KI, Kayagaki N, Okumura K, Yagita H (1997) Antitumor effect of locally produced CD95 ligand. Nature Med 2: 165-170
38. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
39. Strand S, Hofmartn WJ, Hug H, Müller M, Otto G, Strand D, Manani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (Apo1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med 2: 1361-1366
40. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H (1995) Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 55: 5528-5530
41. Tachibana O, Lampe J, Kleihues P, Ohgaki H (1996) Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathol 92: 431-434
42. Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto M, Koh T, Ariyasu T, Tachi M, Kasuga M, Takahashi R (1995) Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946
43. Tanaka M, Itai T, Adachi M, Nagata S (1998) Downregulation of Fas ligand by shedding. Nature Med 4: 31-36
44. Thoma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H (1998) Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas. J Neuropathol Exp Neurol 57: 239-245
45. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res 57: 3331-3334
46. Villunger A, Egle A, Marschitz l, Kos M, Bock G, Ludwig H, Geley S, Kofler R, Greil R (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Stood 90: 12-20
47. Wagenknecht B, Gulbins E, Lang F, Dichgans J, Weller M (1997) Lipoxygenase inhibitors block CD95 ligand-mediated apoptosis of human malignant glioma cells. FEBS Lett 409: 17-23
48. Walker PR, Saas P, Dietrich PY (1997) Role of Fas ligand (CD95L) in immune escape. The tumor cell strikes back. J Immunol 158: 4521-4524
49. Weller M (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res in press
50. Weller M, Fontana A (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128-151
51. Weller M, Constam D, Malipiero U, Fontana A (1994) Transforming growth factor-ß2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression. Eur J Immunol 24: 1293-1300
52. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human malignant glioma cells. Induction and modulation of sensitivity by cytokmes. J Clin Invest 94: 954-964
53. Weller M, Frei K, Malipiero U, Groscurth P, Yonekawa Y, Krammer P, Fontana A (1995) Fas/APO-1-mediated apoptosis of human malignant glioma. Neurology 45(Suppl. 4):859S
54. Weller M, Malipiero UV, Aguzzi A, Reed JC, Fontana A (1995) Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643
55. Weller M, Malipiero U, Rensing-Ehl A, Barr P, Fontana A (1995) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944
56. Weller M, Schmidt C, Roth W, Dichgans J (1997) Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48: 1704-1709
57. Weller M, Weinstock C, Will C, Wagenknecht B, Dichgans J, Lang F, Gulbins E (1997) CD95-dependent T cell killing by glioma cells expressing CD95 ligand: more on tumor immune escape, the CD95 counterattack, and the immune privilege of the brain. Cell Physiol Biochem 7: 282-288
58. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P (1997} Topoisomerase I inhibitors for human malignant glioma. Differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int J Cancer 73:707-714
59. Wen PY, Lampson MA, Lampson LA (1992) Effects of ginterferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy. J Neuroimmunol 36: 57-68
60. Winter S, Roth W, Dichgans J, Weller M (1998) Synergistic activity of CD95 ligand and teniposide (VM26) does not involve enhanced formation of cleavable DNA complexes or changes in CD95/CD95 ligand expression. Eur J Pharmacol in press
61. Wong GHW, Bartlett PF, dark-Lewis I, Battye F, Schrader JW (1984) Inducible expression of H-2 and la antigens on brain cells. Nature 310: 688-691
62. Yoshida J. Wakabayashi T, Mizuno M, Sugita K. Yoshida T, Hon S, Mori T, Sato T, Karashima A, Kunsu K, Kiya K, Uozumi T (1992) Clinical effect of intra-arterial tumor necrosis factor-a for malignant glioma. J Neurosurg 77: 78-83
63. Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA (1996) Retroviral delivery and tetracyctinedependent expression of IL-1β-convertmg enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Res 56: 5423-5427
64. Zhang H, Yang Y, Horton JL, Samoilova EB, Judge TA, Turka LA, Wilson JM, Chen Y (1997) Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 100. 1951-1957
65. Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH, Weller M (1997) Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol 159: 2108-2115
66. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFartand HF, Martin R (1998) Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing remitting multiple sclerosis. Ann Neurol in press
67. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M (1998) Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. J Neuroimmunol in press